7 research outputs found
市民社会のプレーヤー交代劇と政治-仁平典宏の<贈与のパラドックス>論を読み解く-
千葉大学大学院人文社会科学研究科研究プロジェクト報告書第257集『都市コミュニティにおける相互扶助と次世代育成』水島治郎 編Sustainable Urban Communities: Communality and Generativity Report on the Research Projects No.25
Additional file 12: Figure S9A and B. of Development and clinical application of an integrative genomic approach to personalized cancer therapy
CLPB-NADSYN1 gene fusion in patient P0002. a Long-range PCR confirms CLPB-NADSYN1 gene fusion. b Genomic breakpoint of CLPB-NADSYN1 gene fusion. (ZIP 150 kb
Additional file 4: Figure S2. of Development and clinical application of an integrative genomic approach to personalized cancer therapy
Detailed workflow of an integrative genomic approach in personalized cancer therapy. (PPTX 303 kb
Additional file 8: Figure S5. of Development and clinical application of an integrative genomic approach to personalized cancer therapy
Correlation of somatic CNA heterozygosity change (median âlog2mBAFâ segment statistic from saasCNV of tumor with respect to normal) between WES and array data. The same partitions are used as in Additional file 7: Figure S4, and weighed correlation in the lower right corner is also computed in the same way. (PPTX 981 kb
Additional file 11: Figure S8. of Development and clinical application of an integrative genomic approach to personalized cancer therapy
A scatter plot of CCND1 gene expression versus log2 copy number ratio (tumor/normal). Each dot represents a patient tumor sample. Tumor types are color-coded. The two breast cancer patients where we reported CCND1 amplification are P0002 and P0040. (PPTX 112 kb
Additional file 3: Figure S1. of Development and clinical application of an integrative genomic approach to personalized cancer therapy
A decision tree approach to predict drug response based on genetic alterations. (PPTX 96 kb
Additional file 9: Figure S6. of Development and clinical application of an integrative genomic approach to personalized cancer therapy
Comparison of weighed correlations of log2ratio (a, data from Additional file 7: Figure S4) and log2mBAF (b, data from Additional file 8: Figure S5) for assays on FFPE- versus frozen-derived tumor DNA material. D statistic and p-value from 2-sided KS test are shown for FFPE- versus frozen-derived correlation distributions (see "Methods" for details on KS test). (PPTX 76 kb